| Biomarker ID | 654 |
| PMID | 21520165 |
| Year | 2012 |
| Biomarker | Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) + Biopsy T-stage + Gleason Score |
| Biomarker Basis | Concentration Based (μg/ml) |
| Biomolecule | Protein |
| Source | Serum |
| Subjects | Humans |
| Regulation | Downregulated in Patients with Gleason Score Upgradation |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Hypoxia and p53 in the cardiovascular system,Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs),TAp63 pathway,Delta Np63 pathway,Ghrelin-mediated regulation of food intake and energy homeostasis |
| Experiment | Gleason Score Upgradation Vs No Gleason Score Upgradation |
| Type of Biomarker | Prognostic |
| Cohort | 52 patients were admitted in the study such that 3 had Gleason Score between 2-4, 32 had GS between 5-6 and 17 had GS 7. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.81; 95% CI 0.69–0.93) |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | ELISA |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | IGFBP3 |